Table 2. Stem celltransplantation characteristics.
| Variable | MCL | LBCL |
|---|---|---|
| Transplantation before LR (all, auto-SCT; n=4) | 2 | 2 |
| Conditioning regimen | ||
| R-BEAM | 1 | 2 |
| Busulfan+melphalan | 1 | 0 |
| Stem cell source Peripheral blood |
2 |
2 |
|
Transplant after LR (n=22) |
13 |
9 |
| Type of transplantation | 13 | 9 |
| Autologous SCT | 0 | 4 |
| Allogeneic SCT | 13 | 5 |
| Interval between 1st and 2nd SCT, median, months(range) | 28(19-36) | 23(16-29) |
| HLA compatibility HLA incompatible |
13 |
5 |
| Matched sibling | 3 | 2 |
| Matched unrelated donor | 10 | 3 |
| Conditioning regimen | 13 | 9 |
| Myeloablative regimen | 0 | 6 |
| Reduced-intensity conditioning | 13 | 3 |
| Fludarabine based | 12 | 3 |
| Others | 1 | 0 |
| Stem cell source | 13 | 9 |
| Bone marrow | 2 | 1 |
| Peripheral blood | 11 | 8 |
| Acute GVHD | 4 | 1 |
| Grade II | 2 | 1 |
| Grade III/IV | 2 | 0 |
| Chronic GVHD | 5 | 4 |
| Limited | 1 | 2 |
| Extensive | 4 | 2 |
Abbreviations: MCL, mantle cell lymphoma; LBCL, large B-cell lymphoma; LR,lenalidomide+rituximab; SCT, stem cell transplantation; R-BEAM, rituximab,carmustine,etoposide,cytarabine,andmelphalan; HLA, human leukocyte antigen; GVHD,graft-versus-host disease.
Data represent number of patients (%) unless otherwise specified.